IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1δ/ɛ and Wnt/β-catenin independent inhibition of mitotic spindle formation.
Casein kinase 1 delta and epsilon (CK1δ/ɛ) are key regulators of diverse cellular growth and survival processes including Wnt signaling, DNA repair and circadian rhythms. Recent studies suggest that they have an important role in oncogenesis. RNA interference screens identified CK1ɛ as a pro-survival factor in cancer cells in vitro and the CK1δ/ɛ-specific inhibitor IC261 is remarkably effective at selective, synthetic lethal killing of cancer cells. The recent development of the nanomolar CK1δ/ɛ-selective inhibitor, PF670462 (PF670) and the CK1ɛ-selective inhibitor PF4800567 (PF480) offers an opportunity to further test the role of CK1δ/ɛ in cancer. Unexpectedly, and unlike IC261, PF670 and PF480 were unable to induce cancer cell death. PF670 is a potent inhibitor of CK1δ/ɛ in cells; nanomolar concentrations are sufficient to inhibit CK1δ/ɛ activity as measured by repression of intramolecular autophosphorylation, phosphorylation of disheveled2 proteins and Wnt/β-catenin signaling. Likewise, small interfering RNA knockdown of CK1δ and CK1ɛ reduced Wnt/β-catenin signaling without affecting cell viability, further suggesting that CK1δ/ɛ inhibition may not be relevant to the IC261-induced cell death. Thus, while PF670 is a potent inhibitor of Wnt signaling, it only modestly inhibits cell proliferation. In contrast, while sub-micromolar concentrations of IC261 neither inhibited CK1δ/ɛ kinase activity nor blocked Wnt/β-catenin signaling in cancer cells, it caused a rapid induction of prometaphase arrest and subsequent apoptosis in multiple cancer cell lines. In a stepwise transformation model, IC261-induced killing required both overactive Ras and inactive p53. IC261 binds to tubulin with an affinity similar to colchicine and is a potent inhibitor of microtubule polymerization. This activity accounts for many of the diverse biological effects of IC261 and, most importantly, for its selective cancer cell killing.
Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore.
J K
JK
Cheong
T H
TH
Nguyen
H
H
Wang
P
P
Tan
P M
PM
Voorhoeve
S H
SH
Lee
D M
DM
Virshup
D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism; D017209:Apoptosis / Q000187:drug effects*; D048149:Casein Kinase 1 epsilon / Q000037:antagonists & inhibitors* / Q000378:metabolism; D048148:Casein Kinase Idelta / Q000037:antagonists & inhibitors* / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects*; D045744:Cell Line, Tumor; D000072261:Dishevelled Proteins; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D009369:Neoplasms / Q000378:metabolism; D010696:Phloroglucinol / Q000031:analogs & derivatives* / Q000494:pharmacology; D010750:Phosphoproteins / Q000378:metabolism; D010766:Phosphorylation; D011720:Pyrazoles / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D034741:RNA, Small Interfering / Q000235:genetics; D008941:Spindle Apparatus / Q000187:drug effects*; D051153:Wnt Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D051176:beta Catenin / Q000037:antagonists & inhibitors* / Q000378:metabolism
C560271:3-(3-chlorophenoxymethyl)-1-(tetrahydropyran-4-yl)-1H-pyrazolo(3,4-d)pyrimidin-4-ylamine; D048868:Adaptor Proteins, Signal Transducing; D000072261:Dishevelled Proteins; C411652:IC 261; D007211:Indoles; D010750:Phosphoproteins; D011720:Pyrazoles; D011743:Pyrimidines; D034741:RNA, Small Interfering; D051153:Wnt Proteins; D051176:beta Catenin; C522839:PF-670462; D010696:Phloroglucinol; D048149:Casein Kinase 1 epsilon; D048148:Casein Kinase Idelta
Mol Cell Biol. 2005 Apr;25(7):2795-807
15767683
Cancer Res. 2004 Jul 1;64(13):4621-8
15231674
J Biol Chem. 1995 Nov 3;270(44):26123-8
7592815
J Cell Biol. 2001 Sep 3;154(5):983-93
11524435
Cancer Cell. 2004 Aug;6(2):171-83
15324700
Cell. 1998 Jul 10;94(1):97-107
9674431
Gut. 2008 Jun;57(6):799-806
18203806
PLoS One. 2010 Feb 01;5(2):e8979
20126544
Cancer Cell. 2003 Oct;4(4):311-9
14585358
Oncogene. 2005 Dec 1;24(54):7964-75
16027726
J Immunol Methods. 1997 May 26;204(2):205-8
9212838
Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1182-7
11818547
Cancer Cell. 2005 Jul;8(1):7-12
16023594
J Cell Sci. 2010 Oct 1;123(Pt 19):3357-67
20826466
Cell Signal. 2007 Mar;19(3):610-6
17027228
J Biol Chem. 1998 Jun 26;273(26):15980-4
9632646
Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16472-7
18948591
JAMA. 2004 Jul 28;292(4):419-22
15280324
Genes Dev. 2006 Feb 15;20(4):399-410
16481469
Cancer Res. 2009 Mar 1;69(5):1910-5
19223556
Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12548-52
10535959
Biochem J. 2007 Dec 15;408(3):297-315
17850214
Mol Cell Biol. 2009 Mar;29(6):1452-8
19139270
J Biol Chem. 2000 Jun 30;275(26):20052-60
10749871
FEBS J. 2009 Dec;276(23):6971-84
19860830
Psychopharmacology (Berl). 2009 Jul;204(4):735-42
19277609
Top Curr Chem. 2009;286:259-78
23563615
Science. 2001 Feb 9;291(5506):1040-3
11232563
Cell. 1998 Jul 10;94(1):83-95
9674430
Genome Biol. 2008;9(6):R92
18518968
Oncogene. 1999 May 20;18(20):3135-42
10340385
J Pharmacol Exp Ther. 2007 Aug;322(2):730-8
17502429
Cancer Cell. 2008 Aug 12;14(2):111-22
18656424
Onkologie. 2005 Oct;28(10):508-14
16186692
Cancer Res. 2007 Dec 15;67(24):11487-92
18089775
Psychopharmacology (Berl). 2009 May;203(4):703-11
19050854
IUBMB Life. 2001 Feb;51(2):73-8
11463166
Oncogene. 2000 Nov 9;19(47):5303-13
11103931
J Biol Chem. 2001 Aug 31;276(35):33147-55
11425858
Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8
18077363
J Biol Chem. 1998 Jan 16;273(3):1357-64
9430669
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
9843981
Cold Spring Harb Symp Quant Biol. 2007;72:413-20
18419299
Nature. 1999 Sep 23;401(6751):345-50
10517632
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21
11309499
J Pharmacol Exp Ther. 2009 Aug;330(2):430-9
19458106
Neuron. 2008 Apr 10;58(1):78-88
18400165